Experimental new drug results in up to 24pct weight loss, comes in a pill
By
Deena Beasley
, Reuters
The full trial results were presented at the annual meeting of the American Diabetes Association in Chicago and published in the Lancet medical journal.
Photo:
123rf
Novo Nordisk on Friday (local time) said full results from early-stage trials show that its experimental drug, amycretin, helped overweight and obese adults lose up to 24 percent of their weight as the Danish company readies for late-stage studies to start next year.
The company said side effects of the drug, tested as both a weekly injection and a daily pill, were mostly gastrointestinal with rates similar to other recent weight loss drugs.
The [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)01185-7/abstract full trial results[ were presented at the annual meeting of the American Diabetes Association in Chicago and published in the
Lancet
medical journal.
Novo's head of development Martin Holst Lange said the Phase 3 amycretin program starting in 2026 will run "for a couple of years" after which the regulatory review process could start.
The company earlier this month said it planned to start late-stage trials of the drug in the first quarter of 2026 after previously announcing the early-stage trial results.
Amycretin has a dual-mode action. Like Novo's popular weight-loss drug Wegovy, it mimics the gut hormone GLP-1, but also targets receptors for a hunger-suppressing pancreatic hormone called amylin.
Trial results showed that 20-milligram weekly injections of the drug helped overweight or obese patients without diabetes lose 22 percent of their weight over 36 weeks, with a 60-mg dose resulting in 24.3 percent weight loss.
In the Phase 1 study of once-daily oral amycretin, patients received increasing doses, ranging from 3 mg to a final dose of 100 mg. Patients who took 50 mg of amycretin at the end of the 12-week trial reduced body weight by 10.4 percent on average, while those taking the maximum dose lost 13.1 percent of their weight, the company said.
Novo said the weight loss did not plateau, suggesting that longer treatment could lead to greater weight loss.
In a
Lancet
commentary, researchers not involved in the amycretin studies said that "while additional weight loss is welcome and helpful, our evolving concept of obesity management has now shifted towards an emphasis on the reduction of the risks and burdens of cardiovascular disease and other comorbidities".
Commentators Tricia Tan, professor of metabolic medicine and endocrinology at Imperial College London, and endocrinologist Dr Bernard Khoo, said studies directly comparing GLP-1 drugs like Novo's Ozempic to drugs like amycretin will be needed to definitively establish their added value and place in obesity management.
- Reuters
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
RNZ News
20 hours ago
- RNZ News
Experimental new drug results in up to 24pct weight loss, comes in a pill
By Deena Beasley , Reuters The full trial results were presented at the annual meeting of the American Diabetes Association in Chicago and published in the Lancet medical journal. Photo: 123rf Novo Nordisk on Friday (local time) said full results from early-stage trials show that its experimental drug, amycretin, helped overweight and obese adults lose up to 24 percent of their weight as the Danish company readies for late-stage studies to start next year. The company said side effects of the drug, tested as both a weekly injection and a daily pill, were mostly gastrointestinal with rates similar to other recent weight loss drugs. The [ full trial results[ were presented at the annual meeting of the American Diabetes Association in Chicago and published in the Lancet medical journal. Novo's head of development Martin Holst Lange said the Phase 3 amycretin program starting in 2026 will run "for a couple of years" after which the regulatory review process could start. The company earlier this month said it planned to start late-stage trials of the drug in the first quarter of 2026 after previously announcing the early-stage trial results. Amycretin has a dual-mode action. Like Novo's popular weight-loss drug Wegovy, it mimics the gut hormone GLP-1, but also targets receptors for a hunger-suppressing pancreatic hormone called amylin. Trial results showed that 20-milligram weekly injections of the drug helped overweight or obese patients without diabetes lose 22 percent of their weight over 36 weeks, with a 60-mg dose resulting in 24.3 percent weight loss. In the Phase 1 study of once-daily oral amycretin, patients received increasing doses, ranging from 3 mg to a final dose of 100 mg. Patients who took 50 mg of amycretin at the end of the 12-week trial reduced body weight by 10.4 percent on average, while those taking the maximum dose lost 13.1 percent of their weight, the company said. Novo said the weight loss did not plateau, suggesting that longer treatment could lead to greater weight loss. In a Lancet commentary, researchers not involved in the amycretin studies said that "while additional weight loss is welcome and helpful, our evolving concept of obesity management has now shifted towards an emphasis on the reduction of the risks and burdens of cardiovascular disease and other comorbidities". Commentators Tricia Tan, professor of metabolic medicine and endocrinology at Imperial College London, and endocrinologist Dr Bernard Khoo, said studies directly comparing GLP-1 drugs like Novo's Ozempic to drugs like amycretin will be needed to definitively establish their added value and place in obesity management. - Reuters
RNZ News
2 days ago
- RNZ News
Elon Musk's SpaceX rockets keep blowing up at worst possible time
By Hadas Gold , CNN Another SpaceX Starship goes up in flames. Photo: NASASpaceflight Analysis: As Elon Musk returns his focus to his businesses, one of his most important companies just had another setback: a SpaceX Starship rocket exploded in an immense fireball on Wednesday during a routine ground test. The explosion marks the fourth failure in a row for SpaceX's Starship, all while Musk's other companies and his personal brand struggle to recover after his foray into politics. Starship is supposed to help reach NASA's goal of bringing American astronauts back to the moon by 2027: The US space agency is paying SpaceX up to about US$4 billion for the mission. Although SpaceX has said that the last three launches before Wednesday's explosions were successful in testing some elements, all ended in mid-flight failures. SpaceX has long made the case that failures during the testing and development phase are not the harbingers of disaster they may seem. The company embraces a design philosophy called "rapid iterative development" that emphasises building relatively low-cost prototypes and launching frequent test flights. SpaceX believes the approach allows the company to hash out rocket designs faster and at cheaper price points than relying on slower, more methodical engineering approaches that can guarantee a vehicle's success. But the very fiery Starship explosion comes as Musk has been trying to restore his reputation as he returned to focus on his businesses after a controversial stint in the Trump administration. After several months as a top White House adviser and leading the Department of government Efficiency, Musk is now taking a step back from full-time government work refocusing his time on his companies, including Tesla, which has struggled in part as a result of Musk's alliance with the Trump administration. Upon his return, Musk has sought to promote an image of safety and reliability at Tesla, which is aiming to launch its driverless robotaxis in Austin on Sunday - although the initial phase is expected to be limited to less than two dozen cars, and Musk has warned the date could shift. But before the launch, a group of Texas lawmakers have asked Tesla to delay the rollout of its robotaxi service until September, citing a new law on autonomous driving set to take effect. And Tesla's share price slipped this week, before recovering somewhat, following a report from Business Insider that the company plans to pause production on Cybertruck and Model Y lines for a week at its Austin factory for maintenance, the third such shutdown this year. And in Europe, where Tesla sales have been plunging, Chinese car maker BYD sold more pure battery electric vehicles over Tesla in Europe for the first time, according to a report from JATO , an automotive market research firm. Elon Musk Photo: AFP Musk also has his work cut out for him at his AI company, xAI. Bloomberg reported the company "is burning through US$1 billion a month" as the cost of building out its AI model "races ahead of the limited revenues." Musk brushed off the report. "Bloomberg is talking nonsense," he posted on X in response. They don't. Also, Bloomberg is talking nonsense. Musk also publicly disputed his own AI chatbot Grok, when it posted a fact check about politically motivated violence, noting that "Since 2016, data suggests right-wing political violence has been more frequent and deadly." That response lines up with most publicly available data. But Musk didn't agree. "Major fail, as this is objectively false. Grok is parroting legacy media. Working on it." he posted . Musk seems to be brushing off the setbacks, especially with SpaceX. He said last month that he hoped Starship would make its inaugural flight to Mars by the end of next year - a target that looks increasingly unlikely to be met. "Just a scratch," he posted after Starship's explosion before posting "RIP Ship 36" and memes. When a user asked Musk's chatbot Grok why Musk was posting memes, Grok responded "The timing suggests it's likely a humorous comment on the SpaceX Starship explosion that occurred on June 18, rather than targeting a specific person. Musk often uses memes to downplay such setbacks." Musk responded with a bullseye emoji. -CNN
RNZ News
4 days ago
- RNZ News
"Don't worry, this won't hurt"
Don't worry, this won't hurt. When has that ever turned out to be true? Parents may try to ease a child's anxiety about a medical procedure with a white lie. But lies that mislead children about their experiences are not white lies, says Allison Sweet Grant. She endured terrible pain as a child from surgery to correct one leg that was shorter than the other. In her debut novel for young adults, Grant explores themes of agency, trust, and betrayal through a 19-year-old character facing the same medical trauma she did and learning how to heal. The book is called I am the Cage.
